CFS - Chronic Fatigue Syndrome - la sindrome da affaticamento cronico e i gliconutrienti • VULVODINIA.INFO

Mer 16 Nov 2011, 23:21

sindrome da affaticamento cronico

Cosa è
Definizione:
La sindrome da stanchezza cronica è caratterizzata da stanchezza grave e invalidante associata ad altri sintomi, tra i quali dolori muscolari, disturbi del sonno, mancanza di concentrazione e cefalea. Due definizioni largamente usate per la sindrome da stanchezza cronica, quella dei CDC di Atlanta[1] e quella di Oxford[2] sono state utilizzate come criteri operativi per la ricerca . Ci sono importanti differenze tra le definizioni: i criteri inglesi sottolineano la presenza di stanchezza mentale, mentre quelli statunitensi includono tra i requisiti diversi sintomi fisici, riflettendo la convinzione che la sindrome da stanchezza cronica sia la manifestazione di una patologia immunologica o infettiva sottostante.

Bibliografia
1. Fukuda K, Straus S, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994;121:953-959.
2. Sharpe M, Archard LC, Banatvala JE. A report - chronic fatigue syndrome: guidelines for research. J R Soc Med 1991;84:118-121.
Fonte: http://www.cfsitalia.it/Definizione.html

La sindrome da affaticamento cronico e i gliconutrienti
Integr Physiol Behav Sci. 1998 Jul-Sep;33(3):280-7.
The in vitro immunomodulatory effects of glyconutrients on peripheral blood mononuclear cells of patients with chronic fatigue syndrome.
See DM, Cimoch P, Chou S, Chang J, Tilles J.
Source
University of California, Irvine, Department of Medicine, Orange 92668, USA.
Abstract
In humans, eight monosaccharides are required for the synthesis of glycoproteins. Dietary supplements that supply these crucial sugars are known as glyconutrients. A glyconutrient compound was added to Peripheral Blood Mononuclear Cells (PBMC) isolated from normal controls and patients with the Chronic Fatigue Syndrome (CFS), a disease associated with immune dysregulation. The in vitro immunomodulatory effects were investigated. Cell surface expression of the glycoproteins CD5, CD8, and CD11a were significantly lower in patients with CFS compared to normal controls. Addition of glyconutrient homogenate to PBMC from patients with CFS stimulated with phytohemagglutinin significantly increased the expression of each glycoprotein. Furthermore, natural killer (NK) cell function was reduced in CFS patients. The glyconutrient preparation significantly enhanced NK cell activity versus human herpes virus 6 (HHV-6)-infected H9 cells in an 8 h 51Cr release assay compared to placebo for PBMC from patients with CFS (p< .01). Finally, apoptosis was significantly higher in patients with CFS. The percentage of apoptotic cells was significantly decreased in PBMC from patients with CFS that had been incubated for 48 h with glyconutrients. Thus, glyconutrients improved abnormal immune parameters in vitro in patients with CFS.

Fonte: Pubmed (http://www.ncbi.nlm.nih.gov/pubmed/9829439)